CoChat

Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis

Tonstad, Serena, Davies, Simon, Flammer, Martina, Russ, Cristina, Hughes, John · 2010 · Drug Safety

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Background Varenicline (Chantix), Champix) has shown efficacy and tolerability as an aid to smoking cessation. In postmarketing surveillance, neuropsychiatric symptoms have appeared; however, their incidence and causal relationship to varenicline is not known. Objective We assessed the incidence and relative risk (RR) of psychiatric disorders in ten randomized, double-blind, placebo-controlled trials of varenicline for smoking cessation. Methods All smoking cessation phase II, III and IV randomized controlled clinical trials of varenicline versus placebo completed as of 31 December 2008, on file with the manufacturer (Pfizer, Inc.), were included. All studies have been published. All 3091 participants who received at least one dose of varenicline and all 2005 participants who received placebo were included in this analysis. These were men and women smoking > or =10 cigarettes/day, aged 18-75 years and without current psychiatric disease who received varenicline or placebo for 6 (one study), 12 (eight studies) or 52 (one study) weeks. Adverse events were recorded at each study visit and classified according to standard Medical Dictionary for Regulatory Activities (MedDRA) terms (version 11.0). Results The incidence of psychiatric disorders other than solely sleep disorders and disturbances was 10.7% in subjects treated with varenicline and 9.7% in subjects treated with placebo, with an RR of 1.02 (95% CI 0.86, 1.22). The RRs (95% CI) versus placebo of psychiatric adverse event…

Overview

Integrity signals

Registry

Crossref · 10.2165/11319180-000000000-00000

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 6

  1. Cahill, 2008, Cochrane Database Syst Rev, &NA;, CD006103
  2. Hughes, 2007, Cochrane Database Syst Rev, &NA;, CD000031
  3. Stead, 2008, Cochrane Database Syst Rev, &NA;, CD000146
  4. Kutscher, 2009 May, S D Med, 62, 193
  5. Agresti, 2000 Apr 30, Stat Med, 19, 1115, 10.1002/(SICI)1097-0258(20000430)19:8<1115::AID-SIM408>3.0.CO;2-X · DOI · Paper page
  6. Gunnell, 2009, BMJ, 339, 1072

Cited by

See all 142

Metadata

Authors
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J.
Affiliations
  • Oslo University Hospital (NO)
  • Pfizer (United States) (US)
  • University of Vermont (US)
Corresponding author
Tonstad, Serena
Venue
Drug Safety
Published
2010-04
Volume
33
Issue
4
Pages
289-301
ISSN
0114-5916 (ISSN-L)
OpenAlex
W2055445378
Cited by
142
References
50
Citations by year
2025: 2 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 12 · 2015: 18 · 2014: 8 · 2013: 18 · 2012: 25
FWCI
16.14
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Pfizer
  • Sanofi
  • University of Vermont
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
varenicline, psychiatric adverse events, smoking cessation, neuropsychiatric symptoms, anxiety disorders, mood disorders, sleep disorders, relative risk, adverse event incidence, suicidal ideation, nicotine receptor partial agonist, antidepressant side effects, antidepressant withdrawal symptoms, antidepressant-induced mania, antidepressant-induced hypomania
MeSH terms
Varenicline, Adolescent, Adult, Aged, Mental Disorders, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Quinoxalines, Risk, Sleep Wake Disorders, Incidence, Randomized Controlled Trials as Topic, Smoking Cessation, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis. https://app.cochat.ai/papers/10.2165/11319180-000000000-00000
The paper
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010). Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline: A Pooled Analysis. Drug Safety. https://doi.org/10.2165/11319180-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.